Evotec and Variant Bio collaborate for fibrosis treatment
Seeking Alpha News (Thu, 18-Apr 8:25 AM ET)
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments
ACCESSWIRE (Thu, 18-Apr 7:47 AM ET)
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
PRNewswire (Thu, 18-Apr 7:27 AM ET)
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
ACCESSWIRE (Wed, 17-Apr 9:19 AM ET)
Evotec welcomes Aurlie Dalbiez as Chief People Officer
ACCESSWIRE (Wed, 17-Apr 1:50 AM ET)
ACCESSWIRE (Wed, 6-Mar 1:51 AM ET)
PRNewswire (Wed, 21-Feb 9:25 AM ET)
PRNewswire (Tue, 20-Feb 2:53 AM ET)
ACCESSWIRE (Wed, 7-Feb 2:00 AM ET)
Evotec SE: Invitation to Conference Call
ACCESSWIRE (Mon, 22-Jan 2:01 AM ET)
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The EVT Execute segment, about 75% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment, about 25% of sales, develops proprietary drug discovery programs and assets, which can lead to partnerships with clients. As of 2022, the company has almost 5,000 employees and 17 production sites mainly in Europe and the United States.
Evotec Se - American Depositary Shares Each Representing 1/2 Of One Ordinary Share trades on the NASDAQ stock market under the symbol EVO.
As of April 18, 2024, EVO stock price declined to $7.15 with 25,924 million shares trading.
EVO has a beta of 2.09, meaning it tends to be more sensitive to market movements. EVO has a correlation of 0.26 to the broad based SPY ETF.
EVO has a market cap of $2.53 billion. This is considered a Mid Cap stock.
Last quarter Evotec Se - American Depositary Shares Each Representing 1/2 Of One Ordinary Share reported $214 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $28 million and missed earnings estimates by -$.07.
The top ETF exchange traded funds that EVO belongs to (by Net Assets): APIE, DFSI.
EVO has underperformed the market in the last year with a price return of -32.1% while the SPY ETF gained +22.3%. EVO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.2% and -6.5%, respectively, while the SPY returned +6.1% and -3.8%, respectively.
EVO support price is $7.04 and resistance is $7.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EVO stock will trade within this expected range on the day.